Intro

This chapter explores the treatment of metastatic triple-negative breast cancer, specifically combining chemotherapy with pembrolizumab for PD-1 positive patients. It highlights the significance of personalized treatment strategies based on patient-specific factors and emphasizes the role of data-driven decision-making in therapy selection.